Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ANALYST INTERVIEW: INVESTING IN BIOTECHNOLOGY: FRANKLIN BERGER - JP MORGAN H&Q.


(PAK PAK,
n.pr See pyridoxal-alpha-ketoglutarate.
904) INVESTING IN BIOTECHNOLOGY: FRANKLIN BERGER - JP MORGAN H&Q. Reviews the performance of the industry, and examines recent changes that have impacted companies in that sector. Topics discussed include competition, mergers and acquisitions, and the development of customer demand; and a number of companies are identified that are considered well positioned to succeed in the current market. Sector: Biotechnology. Published date 5/8/02. Tickers featured: ALKS ALKS Alkermes, Inc. (stock symbol) , ALXN, AMGN, BGEN, CHIR, CVTX, DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
, GILD, IMNX, JNJ, MEDI, MLNM, REGN, SCIO, SGP, SRA, XOMA. Complete text approximately 3000 words. Document # PAK904.

ANALYST INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2002 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:ANALYST INTERVIEW: INVESTING IN BIOTECHNOLOGY: FRANKLIN BERGER - JP MORGAN H&Q.(Brief Article)
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 10, 2002
Words:113
Previous Article:ROUNDTABLE FORUM: ELECTRONIC MANUFACTURING SERVICES.
Next Article:ANALYST INTERVIEW: BIOTECHNOLOGY INVESTMENT ISSUES: DENNIS PURCELL - PERSEUS-SOROS BIOPHARMACEUTICAL FUND.
Topics:



Related Articles
ANALYST INTERVIEW: BIOTECHNOLOGY OVERVIEW: FRANKLIN BERGER - JP MORGAN H&Q.
BIG WIN FOR AMGEN; LEGAL VICTORY IN ANTI-ANEMIA DRUG BATTLE MAY BOOST STOCK PRICE, ANALYSTS SAY.
ANALYST INTERVIEW: THERAPEUTIC-FOCUSED BIOTECHNOLOGY: SRINIVAS AKKARAJU - J.P. MORGAN PARTERS LLC.
U.K. growth fund to invest in hotel chain.
How free-thinking Liverpool sold its charms to JP Morgan; David Cassidy tells Sophie Freeman why the banking giant is setting up here.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles